Iron Deficiency Anemia

Disclaimer: This clinical reference provides general medical information based on current evidence. It is intended for educational purposes and to support, not replace, the clinical judgment of healthcare professionals. Patient care decisions must always be individualized based on a thorough assessment of the patient's condition, medical history, and local guidelines. Consult official guidelines and expert consensus for specific treatment protocols.

Overview

• Definition: Iron deficiency anemia (IDA) is a microcytic, hypochromic anemia characterized by depleted body iron stores, leading to insufficient iron for optimal red blood cell production. It is the most common nutritional deficiency worldwide.

• Epidemiology:

  • Globally, IDA affects over 1.2 billion people and is the leading cause of disability.
  • Prevalence:
    • Women of childbearing age: Approximately 15-20% in developed countries, significantly higher (up to 40-50%) in developing countries.
    • Pregnant women: Up to 40% in developed countries, over 60% in developing countries.
    • Infants and young children (6-24 months): Up to 20-30%.
    • Adolescents: Significant prevalence due to growth spurts and menstruation.
    • Elderly: Up to 10-15%, often multifactorial (poor diet, chronic disease, GI bleeding).
    • Individuals with chronic kidney disease (CKD), inflammatory bowel disease (IBD), heart failure, or bariatric surgery: High prevalence.

• Classification: IDA is primarily classified by its underlying cause rather than distinct subtypes. However, iron deficiency can exist on a spectrum:

  • Latent Iron Deficiency: Decreased iron stores (low ferritin) without anemia (normal hemoglobin).
  • Iron-Deficient Erythropoiesis: Decreased iron stores and impaired red blood cell production (low ferritin, low transferrin saturation, normal Hb).
  • Iron Deficiency Anemia (IDA): Decreased iron stores with overt anemia (low ferritin, low transferrin saturation, low Hb, microcytic hypochromic red cells).

Pathophysiology

• Mechanism: Iron is essential for hemoglobin synthesis. IDA develops when the body's iron stores are insufficient to meet the demands for erythropoiesis.

  • Iron Metabolism: Dietary iron (primarily non-heme iron from plants, heme iron from meat) is absorbed primarily in the duodenum and proximal jejunum. Ferric iron (Fe3+) is reduced to ferrous iron (Fe2+) by duodenal cytochrome B (DMT1) and transported into enterocytes via divalent metal transporter 1 (DMT1). Inside the cell, iron is either stored as ferritin or transported across the basolateral membrane by ferroportin. Once outside the enterocyte, Fe2+ is oxidized back to Fe3+ by hephaestin and binds to transferrin for transport to various tissues, especially the bone marrow for erythropoiesis.
  • Hepcidin: A key regulator of iron homeostasis, hepcidin is a hormone produced by the liver. It inhibits iron absorption from the gut and iron release from macrophages by binding to and degrading ferroportin. In IDA, hepcidin levels are appropriately low, allowing for increased iron absorption. In anemia of chronic disease (ACD), hepcidin levels are inappropriately high due to inflammation, leading to iron sequestration and impaired utilization.
  • Progression of Deficiency:
    1. Stage 1 (Iron Depletion): Iron stores are reduced (low ferritin), but serum iron and hemoglobin remain normal.
    2. Stage 2 (Iron-Deficient Erythropoiesis): Iron stores are depleted, and iron supply to bone marrow is limited (low ferritin, low transferrin saturation, elevated red cell protoporphyrin), but hemoglobin may still be normal or mildly decreased.
    3. Stage 3 (Iron Deficiency Anemia): Hemoglobin levels fall below the lower limit of normal, and red blood cells become microcytic and hypochromic.

• Risk Factors:

  • Increased Iron Loss:
    • Chronic Blood Loss: Most common cause in adults.
      • Gastrointestinal (GI) bleeding: Peptic ulcers, gastritis, NSAID use, angiodysplasia, diverticulosis, inflammatory bowel disease, GI malignancies (colorectal cancer), hemorrhoids. Always suspect GI blood loss in adult males and postmenopausal women with IDA.
      • Menstrual blood loss: Heavy menstrual bleeding (menorrhagia), uterine fibroids.
      • Urinary tract bleeding: Hematuria.
      • Frequent blood donation.
      • Surgical blood loss, trauma.
      • Frequent phlebotomy (e.g., for polycythemia vera).
  • Decreased Iron Intake/Absorption:
    • Dietary Deficiency: Vegan/vegetarian diets (lower bioavailability of non-heme iron), unbalanced diets.
    • Malabsorption Syndromes: Celiac disease, atrophic gastritis, H. pylori infection, inflammatory bowel disease, bariatric surgery (gastric bypass), achlorhydria (e.g., due to proton pump inhibitors, antacids).
    • Gastrectomy/Bowel Resection: Reduced surface area for absorption.
    • Lead poisoning: Can impair iron metabolism (rare primary cause).
  • Increased Iron Requirements:
    • Pregnancy: Increased maternal red cell mass and fetal iron demands.
    • Lactation: Iron transferred to breast milk.
    • Rapid Growth: Infancy, adolescence.
    • Erythropoietin (EPO) therapy: In chronic kidney disease, increases demand for iron.
  • Inflammation/Chronic Disease: While primary cause is often blood loss or poor intake, chronic inflammation (e.g., rheumatoid arthritis, cancer, CKD, chronic infections) can contribute by increasing hepcidin, leading to functional iron deficiency (iron trapped in macrophages).

• Protective Factors:

  • Dietary Iron: Consumption of iron-rich foods (red meat, poultry, fish, fortified cereals, legumes, leafy greens).
  • Vitamin C Intake: Enhances absorption of non-heme iron when consumed concurrently.
  • Appropriate Iron Supplementation: In high-risk groups (pregnant women, infants, some menstruating women).
  • Diagnosis and Management of Underlying Causes: Prompt identification and treatment of conditions leading to chronic blood loss or malabsorption.

Clinical Presentation

Symptoms of IDA typically develop insidiously and are often non-specific, correlating with the severity and chronicity of the anemia.

Signs and Symptoms

• Cardinal Features:

  • Fatigue and Weakness: Most common and often the earliest symptoms.
  • Dyspnea on Exertion: Shortness of breath with activity.
  • Pallor: Pale skin, conjunctivae, mucous membranes, and palmar creases (best assessed in conjunctivae).
  • Tachycardia and Palpitations: Due to compensatory increase in cardiac output.
  • Dizziness/Lightheadedness: Especially on standing (orthostatic).
  • Headache: Common.

• Early Signs: Often subtle and non-specific, may include mild fatigue, decreased exercise tolerance, irritability, difficulty concentrating.

• Advanced Signs: Develop with prolonged and severe iron deficiency.

  • Koilonychia: Spoon-shaped, brittle fingernails.
  • Glossitis: Smooth, painful, red tongue due to atrophy of papillae.
  • Angular Cheilitis: Fissures at the corners of the mouth.
  • Pica: Craving and compulsive consumption of non-nutritive substances (ice "pagophagia," dirt "geophagia," starch "amylophagia"). Specific for IDA.
  • Restless Legs Syndrome (RLS): Unpleasant sensations in the legs, relieved by movement, often worse at rest.
  • Dysphagia: Difficulty swallowing, often due to esophageal webs (Plummer-Vinson syndrome, rare).
  • Hair Thinning/Loss: Diffuse alopecia.
  • Cold Intolerance: Feeling cold frequently.
  • Cognitive Impairment: Reduced concentration, memory problems, particularly in children and elderly.

• Atypical Presentations:

  • Exercise Intolerance without overt dyspnea.
  • Irritability and behavioral changes in children.
  • Reduced academic performance in school-aged children.
  • Immune dysfunction: Increased susceptibility to infections (though less direct evidence).

Physical Examination

• Inspection:

  • Pallor: Observe the conjunctivae (lower palpebral conjunctiva should be pink), palmar creases (less reliable than conjunctival pallor), nail beds, and skin.
  • Koilonychia: Examine fingernails for spoon shape, brittleness, longitudinal ridging.
  • Glossitis: Inspect the tongue for redness, smoothness, and absence of papillae.
  • Angular Cheilitis: Look for cracks or fissures at the corners of the mouth.
  • Jaundice: Absent in IDA. If present, suggests hemolysis or liver disease.
  • Edema: Peripheral edema in severe cases due to high-output heart failure.

• Palpation:

  • Tachycardia: Assess heart rate.
  • Spleen: Usually non-palpable; rarely mildly enlarged if underlying cause is systemic (e.g., myelodysplastic syndrome, though not directly caused by IDA).
  • Lymph nodes: Usually not enlarged.

• Special Tests:

  • Orthostatic Vital Signs: Check for orthostatic hypotension if severe anemia or suspected hypovolemia from acute blood loss.
  • Cardiac Auscultation: Listen for flow murmurs (systolic murmur at the left sternal border) due to increased cardiac output. Signs of heart failure (S3 gallop, crackles) in severe, prolonged cases.

Diagnostic Approach

The diagnostic approach for IDA involves confirming the iron-deficient state and, crucially, identifying the underlying cause.

History Taking

• Key Questions:

  • Duration and Progression of Symptoms: Onset of fatigue, pallor, dyspnea.
  • Dietary Habits: Vegan/vegetarian, intake of iron-rich foods, consumption of iron absorption inhibitors (e.g., tea, coffee with meals).
  • Blood Loss:
    • Gastrointestinal: History of peptic ulcer disease, GERD, NSAID use, hemorrhoids, diverticulosis, inflammatory bowel disease, any changes in bowel habits (diarrhea, constipation), blood in stool (melena, hematochezia), dark stools, history of endoscopy/colonoscopy. For all adult males and postmenopausal females with IDA, consider GI workup for occult blood loss, especially malignancy.
    • Menstrual: For premenopausal women, inquire about duration, frequency, number of pads/tampons used, presence of clots, flooding, intermenstrual bleeding. Quantify blood loss if possible.
    • Other: Nosebleeds, gum bleeding, hematuria, frequent blood donations, recent surgery or trauma.
  • Medication History: Anticoagulants (aspirin, NSAIDs, warfarin, DOACs), proton pump inhibitors, antacids (affect iron absorption).
  • Past Medical History: Gastric bypass or other bariatric surgery, celiac disease, IBD, H. pylori infection, chronic kidney disease, history of malignancy, liver disease.
  • Family History: Anemia, bleeding disorders, GI malignancy, celiac disease.
  • Pica: Ask specifically about cravings for ice, dirt, or other non-food items.
  • Travel History: Especially to areas with high hookworm prevalence.

• Red Flags:

  • Acute/Severe Anemia: Hemoglobin <7 g/dL or symptomatic (chest pain, severe dyspnea, syncope) requiring urgent transfusion.
  • Signs of Active Bleeding: Hemodynamic instability, overt GI bleeding.
  • Age > 50 with New-Onset IDA: High suspicion for GI malignancy (colorectal cancer in particular), especially in males and postmenopausal females. Requires prompt GI evaluation (endoscopy, colonoscopy).
  • Unexplained Weight Loss, Changes in Bowel Habits, Abdominal Pain: Suggestive of GI malignancy or chronic inflammatory conditions.

Laboratory Tests

• First-Line:

  • Complete Blood Count (CBC):
    • Hemoglobin (Hb): Reduced (anemia). Normal values vary by age/sex (e.g., adult males: 13.5-17.5 g/dL; adult females: 12.0-15.5 g/dL).
    • Mean Corpuscular Volume (MCV): Typically low (<80 fL), indicating microcytosis.
    • Mean Corpuscular Hemoglobin (MCH): Low, indicating hypochromia.
    • Mean Corpuscular Hemoglobin Concentration (MCHC): Low, indicating hypochromia.
    • Red Cell Distribution Width (RDW): Often elevated (>14.5%), indicating anisocytosis (variation in red cell size) due to mixed populations of normal and microcytic cells.
    • Platelet Count: Can be normal, elevated (reactive thrombocytosis in response to iron deficiency or bleeding), or rarely low.
    • White Blood Cell Count: Usually normal.
  • Peripheral Blood Smear: Hypochromic (pale center), microcytic (small) red blood cells, sometimes "pencil" cells or "target" cells.

• Confirmatory:

  • Serum Ferritin: Most sensitive and specific test for iron deficiency. Reflects body iron stores.
    • Value < 30 ng/mL (or mcg/L) is diagnostic of iron deficiency in the absence of inflammation.
    • Value < 100 ng/mL with transferrin saturation <20% is diagnostic for IDA in the presence of inflammation (e.g., chronic kidney disease, inflammatory bowel disease, chronic infection, malignancy).
    • Note: Ferritin is an acute-phase reactant, so it can be falsely elevated in inflammatory conditions, liver disease, or malignancy, masking true iron deficiency.
  • Serum Iron: Typically low.
  • Total Iron-Binding Capacity (TIBC): Represents the total capacity of transferrin to bind iron. Typically elevated in IDA (unbound transferrin increases).
  • Transferrin Saturation (TSAT): (Serum Iron / TIBC) x 100%. Represents the percentage of transferrin binding sites occupied by iron. Typically low (<20%) in IDA.
  • Reticulocyte Hemoglobin Content (CHr/Ret-He): Newer, more direct measure of hemoglobinization of reticulocytes. Low values (<28 pg) indicate iron-restricted erythropoiesis. Useful in distinguishing IDA from ACD.
  • Soluble Transferrin Receptor (sTfR): Levels increase in proportion to iron deficiency and iron-restricted erythropoiesis. Not affected by inflammation. Elevated sTfR/ferritin index can help differentiate IDA from ACD.

• Monitoring:

  • CBC (Hb, MCV): After 2-4 weeks of iron therapy to assess response (reticulocyte count may peak around 7-10 days, Hb rise typically begins after 2-4 weeks). Monitor every 2-4 weeks initially until Hb normalizes.
  • Serum Ferritin and TSAT: After 3-6 months of therapy to confirm repletion of iron stores. Once Hb is normalized, iron supplementation should continue for at least 3-6 months to replenish stores; ferritin should be rechecked to confirm stores are >100 ng/mL.
  • Follow-up Hb: Every 3-6 months after repletion and then annually, or as clinically indicated, to detect recurrence.

Imaging

• Recommended: Imaging is generally not for the diagnosis of IDA itself, but for identifying the underlying cause, especially chronic blood loss.

  • Upper Endoscopy (EGD) and Colonoscopy: Strongly recommended for adult males and postmenopausal women with IDA, and for premenopausal women if no obvious gynecologic cause or if persistent IDA despite treatment. This is to rule out GI bleeding sources, including malignancy (e.g., peptic ulcer, esophagitis, gastritis, angiodysplasia, diverticulosis, inflammatory bowel disease, colorectal cancer).
  • Pelvic Ultrasound: For premenopausal women with heavy menstrual bleeding to identify structural causes (e.g., uterine fibroids, polyps).
  • CT Enterography/MR Enterography: If small bowel disease (e.g., Crohn's, celiac disease refractory to diagnosis, obscure GI bleeding) is suspected after negative EGD and colonoscopy.

• Advanced:

  • Capsule Endoscopy: For obscure GI bleeding (bleeding not identified by EGD and colonoscopy).
  • Angiography/Nuclear Scintigraphy: In cases of acute, significant GI bleeding where the source cannot be localized by endoscopy.
  • Bone Marrow Biopsy: Rarely needed for diagnosis of IDA; primarily reserved for complex cases where other anemias or underlying hematologic malignancies are suspected (e.g., unexplained non-response to iron therapy, pancytopenia).

Management

Management of IDA has two primary goals: repletion of iron stores and identification/treatment of the underlying cause.

Acute Management

• Immediate:

  • Blood Transfusion: Reserved for severe, symptomatic anemia, or when rapid correction of Hb is necessary due to hemodynamic instability or acute hemorrhage.
    • Indications: Generally, Hemoglobin (Hb) < 7 g/dL (or <8 g/dL in patients with cardiovascular disease or acute bleeding), or symptomatic anemia (e.g., acute coronary syndrome, severe dyspnea, syncope, shock).
    • Target: Transfuse packed red blood cells (PRBCs) to alleviate acute symptoms and improve oxygen-carrying capacity. One unit of PRBCs typically raises Hb by approximately 1 g/dL.
  • Stabilization: Address any active bleeding. For acute GI bleeding, this may involve endoscopic hemostasis, proton pump inhibitor therapy, or surgical intervention.

• Emergency: For life-threatening hemorrhage leading to severe IDA, immediate volume resuscitation and appropriate hemorrhage control measures are paramount, followed by transfusion. IV iron is not an emergency measure for acute anemia correction as it takes days to weeks for erythropoiesis to respond.

Chronic Management

• Pharmacological:

  • Oral Iron Supplementation: First-line therapy for most patients.
    • Agents:
      • Ferrous Sulfate: Most commonly used, cost-effective. Contains 65 mg elemental iron per 325 mg tablet.
      • Ferrous Gluconate: Contains 34 mg elemental iron per 300 mg tablet. May cause less GI upset.
      • Ferrous Fumarate: Contains 106 mg elemental iron per 325 mg tablet.
    • Dosage:
      • Adults: 150-200 mg elemental iron per day. A common regimen is Ferrous Sulfate 325 mg (65 mg elemental iron) 2-3 times daily.
      • Newer evidence suggests alternate-day dosing (e.g., 65 mg elemental iron every other day) may improve absorption and reduce side effects by allowing hepcidin levels to drop between doses. This strategy may be preferred, especially for initial therapy.
      • Children: 3-6 mg/kg/day elemental iron, divided into 1-3 doses.
    • Administration:
      • Take on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption.
      • Coadministration with Vitamin C (e.g., 250-500 mg) can enhance absorption.
      • Avoid taking with: Calcium supplements, antacids, PPIs, tea, coffee, dairy products, or high-fiber foods, which inhibit absorption. Separate by at least 2 hours.
    • Side Effects: Common GI side effects include constipation, nausea, abdominal cramping, dark stools. Strategies to manage: start with lower dose and gradually increase, alternate-day dosing, take with small amount of food (though absorption slightly reduced), stool softeners.
    • Duration: Treatment typically continues for 3-6 months after hemoglobin normalizes to replenish iron stores. Ferritin should be rechecked to ensure it's >100 ng/mL.
  • Intravenous (IV) Iron Supplementation: Reserved for specific indications.
    • Indications:
      • Intolerance to oral iron: Severe GI side effects not manageable by dose adjustment.
      • Malabsorption: Celiac disease (refractory), inflammatory bowel disease, gastric bypass, other malabsorption syndromes.
      • Ongoing significant blood loss: Where oral iron cannot keep pace.
      • Chronic kidney disease (CKD) on erythropoiesis-stimulating agents (ESAs): To optimize response to ESA.
      • Inflammatory conditions: Where high hepcidin levels impair oral iron absorption (e.g., IBD, heart failure).
      • Severe anemia requiring rapid repletion: When transfusion is not indicated or desired (e.g., patient preference, religious reasons).
      • Non-adherence to oral iron.
    • Agents: Multiple formulations with varying safety profiles and dosing schedules.
      • Ferric Carboxymaltose (FCM): e.g., Injectafer®. Can administer high doses (e.g., 750-1000 mg) in a single infusion or two infusions 7 days apart.
      • Iron Dextran: e.g., DexFerrum®, INFeD®. Older, higher risk of hypersensitivity reactions, requires a test dose. Can be given as total dose infusion.
      • Iron Sucrose: e.g., Venofer®. Requires multiple smaller doses (e.g., 100-200 mg over 5-10 sessions).
      • Ferumoxytol: e.g., Feraheme®. Can administer high doses (e.g., 510 mg twice, 3-8 days apart).
      • Iron Isomaltoside 1000 (IIM): e.g., Monoferric®. Can administer high doses (up to 1000 mg in a single dose).
    • Side Effects: Infusion reactions (hypersensitivity, including anaphylaxis, though rare with newer agents), transient hypophosphatemia (especially with FCM), headache, nausea, dizziness, local injection site reactions. Close monitoring during and after infusion is essential.

• Non-pharmacological:

  • Dietary Modification: Educate patients on iron-rich foods (heme iron: red meat, poultry, fish; non-heme iron: fortified cereals, legumes, dark leafy greens, tofu, nuts). Advise combining non-heme iron sources with vitamin C.
  • Avoidance of Inhibitors: Limit tea, coffee, and calcium supplements with iron-rich meals or iron supplements.
  • Address Underlying Cause: This is critical.
    • For GI bleeding: Referral to gastroenterology for endoscopy, colonoscopy, or other investigations. Treatment of ulcers, hemorrhoids, or identification/management of malignancy.
    • For Menorrhagia: Referral to gynecology for evaluation and management (e.g., hormonal therapy, IUD, endometrial ablation, hysterectomy).
    • For Malabsorption: Management of celiac disease (gluten-free diet), H. pylori eradication, or treatment of IBD.

• Monitoring:

  • Initial Response: Check reticulocyte count after 7-10 days of iron therapy (should show a rise, indicating bone marrow response).
  • Hemoglobin (Hb): Check every 2-4 weeks until normalized. An increase of 1-2 g/dL per month is expected.
  • Ferritin and TSAT: Recheck 3 months after Hb normalization, or after completion of 3-6 months of oral iron therapy. The goal is to achieve a ferritin level >100 ng/mL.
  • Long-term: Once iron stores are repleted and the underlying cause addressed, monitor Hb every 6-12 months or as clinically indicated, especially if the cause is chronic or cannot be fully resolved.

Treatment Algorithms

• First-Line:

  1. Confirm IDA: Based on CBC (microcytic, hypochromic anemia, elevated RDW) and iron studies (low ferritin, low TSAT, elevated TIBC).
  2. Investigate and Address Underlying Cause: Crucial for all patients. In adult males and postmenopausal women, this usually involves GI evaluation (EGD, colonoscopy) even if asymptomatic for GI issues. In premenopausal women, assess for heavy menstrual bleeding; if significant, manage; if not, proceed with GI evaluation.
  3. Initiate Oral Iron Supplementation: Ferrous sulfate 325 mg (65 mg elemental iron) daily or every other day. Educate on administration, side effects, and duration.
  4. Monitor Response: Reticulocyte count at 1-2 weeks, Hb every 2-4 weeks.
  5. Continue Iron: For 3-6 months after Hb normalizes to replenish stores. Confirm ferritin >100 ng/mL.

• Second-Line:

  1. Consider IV Iron: If oral iron is ineffective (non-response, intolerance despite adherence/management of side effects, ongoing significant blood loss, malabsorption, CKD on ESAs, severe inflammation).
  2. Refer to Specialist: If underlying cause is complex (e.g., obscure GI bleeding, complex gynecologic issues, refractory malabsorption).

• Refractory Cases: If patient does not respond to adequate oral or IV iron therapy (Hb does not rise or stores are not repleted), reassess:

  1. Adherence: Is the patient taking the iron as prescribed?
  2. Absorption: Is there undiagnosed malabsorption (e.g., celiac, H. pylori, PPI use)? Consider diagnostic tests for these conditions.
  3. Ongoing Blood Loss: Is there an ongoing, undetected source of blood loss (e.g., occult GI bleeding, recurrent menstrual bleeding)? Re-evaluate GI/GU/gynecological systems.
  4. Incorrect Diagnosis: Is it truly IDA? Re-evaluate with full iron panel, consider other microcytic anemias (thalassemia trait, sideroblastic anemia, anemia of chronic disease).
     • Thalassemia Trait: Often has very low MCV but normal RDW and usually normal or high ferritin/TSAT. Hemoglobin electrophoresis is diagnostic.
     • Anemia of Chronic Disease (ACD): Can be microcytic or normocytic, usually has low serum iron and TIBC but normal or high ferritin and low TSAT (<20%). High hepcidin.
     • Sideroblastic Anemia: Can be microcytic, ring sideroblasts on bone marrow biopsy.
  5. Inflammation: Is there significant inflammation (e.g., uncontrolled IBD, rheumatoid arthritis) causing functional iron deficiency despite high ferritin? Consider IV iron.
  6. Concurrent Deficiencies: Are there coexisting folate or B12 deficiencies? (Rare to cause microcytosis in initial IDA).
  7. Rare Causes: Very rare cases may warrant bone marrow biopsy to rule out myelodysplastic syndrome or other marrow disorders.

Complications

• Common:

  • Reduced Physical Performance and Fatigue: Leading to decreased productivity and quality of life.
  • Impaired Cognitive Function: Especially attention, concentration, and memory, particularly in children and adolescents.
  • Pica: Can lead to ingestion of harmful substances.
  • Restless Legs Syndrome: Can significantly disrupt sleep.

• Serious:

  • Cardiovascular Complications: High-output cardiac failure in severe, chronic cases due to compensatory increased cardiac workload.
  • Immunological Impairment: Increased susceptibility to infections.
  • Adverse Pregnancy Outcomes: Increased risk of preterm delivery, low birth weight, and maternal mortality. Iron deficiency during pregnancy can affect fetal brain development.
  • Developmental Delays in Children: Irreversible cognitive and behavioral deficits if iron deficiency occurs during critical periods of brain development.

• Long-term:

  • Persistent Fatigue and Poor Quality of Life: If underlying cause not addressed or iron stores not adequately repleted.
  • Increased Morbidity: Due to chronic organ dysfunction if severe IDA is prolonged.

Prognosis

• Factors:

  • Identification and Treatment of Underlying Cause: Most critical factor. If the cause is not identified and managed, IDA will recur.
  • Severity of Anemia at Diagnosis: More severe anemia takes longer to resolve.
  • Adherence to Iron Therapy: Consistent intake is essential.
  • Presence of Comorbidities: Conditions like malabsorption, inflammatory diseases, or CKD can complicate treatment.
  • Age: Infants and children may have more significant long-term neurodevelopmental consequences.

• Survival: Excellent prognosis with appropriate diagnosis and treatment. IDA itself is rarely fatal unless leading to severe cardiac compromise or associated with life-threatening acute bleeding or underlying malignancy. Mortality is primarily related to the underlying cause (e.g., malignancy, severe bleeding).

• Quality of Life: Significantly improves with resolution of anemia and repletion of iron stores. Fatigue, dyspnea, and other symptoms typically resolve within weeks to months of adequate treatment. Cognitive and developmental improvements are observed in children, though severe, prolonged iron deficiency in infancy may lead to irreversible deficits.

Prevention

• Primary: Preventing initial occurrence of IDA.

  • Dietary Guidance: Encourage consumption of iron-rich foods (heme and non-heme sources). Educate on factors enhancing (vitamin C) and inhibiting iron absorption.
  • Iron Fortification: Fortification of staple foods (flour, cereals) with iron in areas with high prevalence.
  • Targeted Supplementation:
    • Infants: Iron-fortified formula or iron supplements for exclusively breastfed infants after 4-6 months of age (1 mg/kg/day until iron-containing complementary foods are introduced).
    • Pregnant Women: Routine prenatal iron supplementation (e.g., 30-60 mg elemental iron/day, higher if anemic) starting in the first trimester.
    • Premature Infants: Higher iron requirements.
    • Adolescent Girls: During rapid growth and onset of menstruation.
  • Hookworm Eradication Programs: In endemic areas.

• Secondary: Early detection and intervention.

  • Screening:
    • Infants: Universal screening (CBC) at 9-12 months, and again at 4-6 years.
    • Pregnant Women: Initial prenatal visit and again in the third trimester (e.g., 24-28 weeks).
    • High-Risk Populations: Regular screening of hemoglobin and ferritin in patients with chronic kidney disease, inflammatory bowel disease, bariatric surgery, or chronic heart failure.
    • Consider for all menstruating women if symptoms suggestive, or if living in low resource setting.
  • Prompt Diagnosis and Treatment of Underlying Causes: Rapid investigation of bleeding sources (GI, gynecologic) in all patients with confirmed IDA.

• Tertiary: Preventing complications and recurrence.

  • Adequate Iron Repletion: Ensure iron stores are fully replenished (ferritin >100 ng/mL) and not just Hb normalized. Continue iron for 3-6 months after Hb normalizes.
  • Long-Term Monitoring: Especially if the underlying cause cannot be fully resolved (e.g., ongoing heavy menstruation, chronic malabsorption).
  • Patient Education: Emphasize importance of adherence to therapy and dietary modifications.

Special Populations

• Pediatric:

  • Vulnerable Periods: Infancy (especially 6-24 months due to rapid growth, introduction of solids), adolescence (growth spurts, menstruation in girls).
  • Symptoms: Often subtle, non-specific. Can include developmental delays, behavioral problems, cognitive impairment, pica, and poor appetite.
  • Diagnosis: Similar lab tests, but age-specific reference ranges for Hb. Ferritin <12 ng/mL for children <5 years, <15 ng/mL for children >5 years.
  • Treatment: Oral iron (3-6 mg/kg/day elemental iron). Parenteral iron rarely needed.
  • Key: Prevention is crucial due to potential irreversible neurodevelopmental sequelae.

• Geriatric:

  • Multifactorial Etiology: IDA in the elderly is rarely purely dietary. Often associated with chronic diseases, medications (NSAIDs), and underlying GI pathology (e.g., diverticulosis, angiodysplasia, malignancy).
  • Presentation: Symptoms may be masked by other comorbidities or attributed to "aging." Fatigue, cognitive decline, dyspnea.
  • Diagnostic Challenge: Ferritin can be elevated due to inflammation from chronic conditions. Need low TSAT (<20%) alongside ferritin <100 ng/mL for IDA in this context.
  • Management: Aggressive search for GI malignancy is paramount (EGD, colonoscopy, even if asymptomatic). Oral iron can be problematic due to side effects; IV iron is often better tolerated and more effective.

• Pregnancy:

  • Increased Requirements: Iron needs increase significantly in the second and third trimesters (up to 27 mg/day total) due to expanding maternal blood volume and fetal demands.
  • Routine Screening: Recommended at first prenatal visit and again at 24-28 weeks gestation (Hb and ferritin).
  • Prevention/Treatment: Prophylactic oral iron (30-60 mg elemental iron daily) for all pregnant women. If anemic, 60-120 mg elemental iron daily.
  • IV Iron: Indicated for severe anemia, oral iron intolerance/malabsorption, late diagnosis in third trimester, or multiple gestation. Safe in pregnancy (e.g., ferric carboxymaltose after first trimester).
  • Impact: Maternal IDA increases risk of preterm birth, low birth weight, and postpartum depression.

• Comorbidities:

  • Chronic Kidney Disease (CKD): IDA is very common due to reduced EPO production, reduced iron absorption (hepcidin elevation), and blood loss (dialysis). Target ferritin >100 ng/mL and TSAT >20% for these patients. Often requires IV iron.
  • Inflammatory Bowel Disease (IBD): Common due to chronic blood loss, malabsorption, and inflammation-induced functional iron deficiency. Often requires IV iron due to poor oral absorption and active inflammation.
  • Heart Failure (HF): Iron deficiency (with or without anemia) is common in HF patients and is associated with worse symptoms, exercise capacity, and prognosis. IV iron (e.g., FCM) is recommended for symptomatic HF patients with iron deficiency (Hb <15 g/dL, ferritin <100 ng/mL, or ferritin 100-299 ng/mL with TSAT <20%).

Clinical Pearls

• Diagnostic:

  • Always investigate the cause of IDA: Simply treating the anemia without finding the underlying cause is a missed opportunity and may delay diagnosis of serious conditions (e.g., malignancy).
  • Ferritin is key: While low ferritin is diagnostic of iron deficiency, a normal or high ferritin level does not rule out functional iron deficiency if inflammation is present. In such cases, a low TSAT (<20%) is crucial.
  • Distinguish from Thalassemia Trait: If MCV is very low but RDW is normal and iron studies are normal/high, consider thalassemia trait (diagnosed by Hb electrophoresis). Iron therapy is ineffective and potentially harmful in thalassemia.

• Treatment:

  • Patience is a virtue: It takes time for Hb to normalize (weeks to months) and even longer to replenish iron stores. Educate patients on this timeline.
  • Manage side effects: Oral iron side effects are common. Strategies like alternate-day dosing, taking with food (slightly reduced absorption), or switching preparations can improve tolerability.
  • IV iron benefits: For selected patients, IV iron offers rapid repletion, bypasses malabsorption, and improves adherence, leading to faster improvement in symptoms and Hb levels.

• Pitfalls:

  • Failure to investigate the cause: The most common and dangerous pitfall.
  • Stopping iron prematurely: Stopping iron once Hb normalizes but before stores are replenished. Recurrence is highly likely.
  • Assuming dietary cause: Especially in adult males and postmenopausal women, IDA is rarely solely dietary; always suspect blood loss.
  • Treating iron deficiency in anemia of chronic disease with oral iron alone: Oral iron is often ineffective in ACD due to hepcidin-mediated blocking of absorption. IV iron is often preferred.

Recent Updates

• Guidelines:

  • American Society of Hematology (ASH): Emphasizes a thorough diagnostic workup for the underlying cause of IDA in all patients, and highlights the utility of newer IV iron formulations.
  • American Gastroenterological Association (AGA): Recommends endoscopic evaluation for all adult patients with IDA, regardless of age, sex, or GI symptoms, unless a definitive non-GI cause is identified.
  • National Comprehensive Cancer Network (NCCN): Provides specific guidance on iron management in cancer patients, often favoring IV iron due to inflammation and chemotherapy effects.
  • European Society of Cardiology (ESC): Recommends screening for iron deficiency (ferritin <100 ng/mL or TSAT <20% if ferritin 100-299 ng/mL) and IV iron treatment for symptomatic heart failure patients with reduced ejection fraction.

• Evidence:

  • Alternate-day oral iron dosing: Growing evidence suggests that taking oral iron every other day (e.g., 65 mg elemental iron) can significantly improve absorption by allowing hepcidin levels to fall, potentially reducing side effects and improving efficacy compared to daily dosing.
  • Newer IV Iron Formulations: More convenient, safer, and allows for larger single doses, reducing the number of infusions needed (e.g., ferric carboxymaltose, iron isomaltoside). They have largely replaced iron dextran as the preferred IV iron preparations due to lower rates of hypersensitivity reactions.
  • Impact of IDA on non-anemic patients: Research increasingly recognizes the negative impact of iron deficiency without anemia on fatigue, cognitive function, and exercise capacity, suggesting that iron repletion may be beneficial even before anemia develops in certain symptomatic patients (e.g., women with heavy menstrual bleeding, athletes, heart failure patients).

• Controversies:

  • Optimal ferritin threshold for diagnosis and treatment: While <30 ng/mL is standard for absolute iron deficiency, some argue for higher thresholds (<100 ng/mL) in the setting of inflammation or functional iron deficiency, and for symptom improvement.
  • Routine universal screening for IDA: Debate continues regarding cost-effectiveness versus targeted screening in high-risk populations.
  • Role of pre-operative IV iron: Growing interest in pre-operative IV iron to improve iron stores and reduce need for peri-operative transfusions in patients undergoing elective surgery.

Key References

• Guidelines:

  • Camaschella, C. (2019). Iron Deficiency. New England Journal of Medicine, 381(25), 2437-2448. (Excellent review on pathophysiology and diagnosis).
  • American Society of Hematology (ASH) guidelines for the management of iron deficiency anemia (regularly updated, consult their official website).
  • Goddard, A. F. R., et al. (2011). Guidelines for the management of iron deficiency anaemia. Gut, 60(10), 1309-1316. (British Society of Gastroenterology guidelines, foundational for GI workup).
  • Kassebaum, N. J., et al. (2014). Global, regional, and national prevalence and risk factors for anaemia in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Haematology, 6(1): e48-e62.
  • Ponikowski, P., et al. (2022). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 43(1): 165-200. (Includes recommendations for IV iron in heart failure).

• Studies:

  • Tolkien, S. M., et al. (2014). Iron deficiency anaemia: a review of epidemiology, pathophysiology, diagnosis and management. British Journal of Hospital Medicine, 75(5), 284-288.
  • Stoffel, N. U., et al. (2017). Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily doses in iron-depleted women: two open-label, randomized controlled trials. Lancet Haematology, 4(11), e524-e532. (Key study on alternate-day dosing).
  • Anker, S. D., et al. (2009). Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine, 361(25), 2436-2448. (FAIR-HF trial, a landmark study for IV iron in heart failure).

• Reviews:

  • UpToDate. Iron deficiency anemia in adults: Clinical manifestations and diagnosis. (Accessed regularly for latest evidence).
  • UpToDate. Treatment of iron deficiency anemia in adults. (Accessed regularly for latest evidence).
  • Mayo Clinic Proceedings. Iron Deficiency Anemia: A Clinical Review. (Recent comprehensive reviews often available in major medical journals).